natgillin/translations-raw huggingface dataset:
Patients previously treated with immunoglobulin administered intravenously
Bolesnici koji su prethodno liječeni intravenskom primjenom imunoglobulina
Patients previously treated with immunoglobulin administered subcutaneously
Bolesnici koji su prethodno liječeni supkutanom primjenom imunoglobulina
Patients randomised
Broj randomiziranih bolesnika
Patients randomised to 100 mg BID + OBR
Bolesnici randomizirani na delamanid 100 mg BID + OBR
Patients randomised to 5-FU/LV received leucovorin 200 mg/m2 intravenously over 30 minutes, followed by 5-FU 2,000 mg/m2 intravenously over 24 hours, administered on Days 1, 8, 15 and 22 of a 6 week cycle.
Bolesnici randomizirani za 5-FU/LV primili su leukovorin 200 mg/m2 intravenski tijekom 30 minuta, a potom 5-FU 2000 mg/m2 intravenski tijekom 24 sata, primijenjeno 1., 8., 15. i 22. dana 6-ero tjednog ciklusa.
Patients randomised to Cosentyx received 150 mg or 300 mg doses at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Bolesnici randomizirani na Cosentyx primali su doze od 150 mg ili 300 mg u 0., 1., 2. i 3. tjednu, nakon čega je slijedila ista doza svakoga mjeseca počevši od 4. tjedna.
Patients randomised to Cosentyx received 75 mg or 150 mg subcutaneously at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Bolesnici randomizirani na Cosentyx primali su 75 mg ili 150 mg supkutano u 0., 1., 2. i 3. tjednu, nakon čega je slijedila ista doza svakoga mjeseca počevši od 4. tjedna.
Patients randomised to Cosentyx received 75 mg, 150 mg or 300 mg subcutaneously at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
Bolesnici randomizirani na Cosentyx primali su 75 mg, 150 mg ili 300 mg supkutano u 0., 1., 2. i 3. tjednu, nakon čega je slijedila ista doza svaki mjesec počevši od 4. tjedna.
Patients randomised to Galafold in Stage 1 demonstrated statistically significant greater reduction (±SEM) in mean interstitial capillary GL-3 deposition (-0.25±0.10; -39%) at month 6 compared to placebo (+0.07 ± 0.13; +14%) (p=0.008).
Bolesnici koji su bili randomizirani u skupinu koja je primala Galafold u 1. fazi pokazali su statistički značajno veće smanjenje (±SEM) srednjeg taloženja GL-3 u intersticijskim kapilarama (–0,25 ± 0,10; –39 %) u 6. mjesecu u usporedbi sa skupinom koja je primala placebo (+0,07 ± 0,13; +14 %) (p = 0,008).
Patients randomised to ONIVYDE monotherapy received 120 mg/m2 as an intravenous infusion over 90 minutes every 3 weeks.
Bolesnici randomizirani za monoterapiju lijekom ONIVYDE primili su 120 mg/m2 putem intravenske infuzije tijekom 90 minuta svaka 3 tjedna.
Patients randomised to Placebo + OBR
Bolesnici randomizirani na placebo + OBR
Patients randomised to placebo in Stage 1 and switched to Galafold at month 6 (Stage 2) also demonstrated statistically significant decreases in interstitial capillary GL-3 inclusions at month 12 (-0.33±0.15; -58%) (p=0.014).
Bolesnici koji su bili randomizirani u skupinu koja je primala placebo u 1. fazi te koji su prešli na Galafold u 6. mjesecu (2.faza) također su pokazali statistički značajno smanjenje inkluzija GL-3 u intersticijskim kapilarama u 12. mjesecu (–0,33 ± 0,15; –58 %) (p = 0,014).
Patients randomised to placebo who were non-responders at Week 16 (early rescue) and other placebo patients at Week 24 were crossed over to receive Cosentyx (either 75 mg or 150 mg subcutaneously) followed by the same dose every month.
Bolesnici randomizirani na placebo koji nisu imali odgovor u 16. tjednu (ranija primjena Cosentyxa) i drugi bolesnici na placebu u 24. tjednu su prebačeni na Cosentyx (75 mg ili 150 mg supkutano), nakon čega je slijedila ista doza svaki mjesec.
Patients randomised to receive placebo who were non-responders at Week 16 (early rescue) were crossed over to receive Cosentyx (either 150 mg or 300 mg subcutaneously) at Week 16 followed by the same dose every month.
Bolesnici randomizirani na primanje placeba koji nisu imali odgovor u 16. tjednu (ranija primjena Cosentyxa) prebačeni su na Cosentyx (150 mg ili 300 mg supkutano) u 16. tjednu, nakon čega je slijedila ista doza svaki mjesec.
Patients randomised to receive placebo who were responders at Week 16 were crossed over to receive Cosentyx (either 150 mg or 300 mg subcutaneously) at Week 24 followed by the same dose every month.
Bolesnici randomizirani na primanje placeba koji su imali odgovor u 16. tjednu prešli su na primanje Cosentyxa (150 mg ili 300 mg supkutano) u 24. tjednu, nakon čega je slijedila ista doza svaki mjesec.
Patients randomised to Taltz who were sPGA (0,1) responders at Week 12 were re-randomised to receive placebo or Taltz for an additional 48 weeks (UNCOVER-1 and UNCOVER-2); patients randomised to placebo, etanercept or Taltz who were sPGA (0,1) non-responders received Taltz for up to 48 weeks.
Bolesnici randomizirani za liječenje lijekom Taltz koji su u tjednu ostvarili odgovor prema sPGA (od engl. static Physician's Global Assessment) rezultatu (0, 1) bili su ponovno randomizirani za primanje placeba ili lijeka Taltz tijekom dodatnih 48 tjedana (UNCOVER-1 i UNCOVER-2); bolesnici randomizirani za primanje placeba, etanercepta ili lijeka Taltz koji nisu ostvarili odgovor prema sPGA rezultatu (0, 1) primali su lijek Taltz tijekom razdoblja do 48 tjedana.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease.
Bolesnici randomizirani u programu ACTIVE imali su dokumentiranu fibrilaciju atrija (FA), tj. ili permanentnu FA ili najmanje 2 epizode intermitentne FA u zadnjih 6 mjeseci te su imali najmanje jedan od sljedećih faktora rizika: dob ≥75 godina ili 55 do 74 godine te ili dijabetes koji zahtijeva terapiju lijekovima ili dokumentirani prethodni infarkt miokarda ili dokumentiranu bolest koronarnih arterija; ako su primali terapiju za sistemsku hipertenziju; prethodni moždani udar, prolazni ishemijski napadaj (TIA) ili ne-CNS sistemska embolija; disfunkcija lijevog ventrikula s ejekcijskom frakcijom lijevog ventrikula <45% ili dokumentirana periferna vaskularna bolest.
Patients randomized to ONIVYDE+5-FU/LV received ONIVYDE at 80 mg/m2 as an intravenous infusion over 90 minutes, followed by LV 400 mg/m2 intravenously over 30 minutes, followed by 5-FU 2,400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
Bolesnici randomizirani za ONIVYDE+5-FU/LV primali su 80 mg/m2 lijeka ONIVYDE putem intravenske infuzije tijekom 90 minuta, nakon čega je slijedio LV 400 mg/m2 intravenski tijekom 30 minuta te potom 5-FU 2400 mg/m2 intravenski tijekom 46 sati, primijenjeno svaka 2 tjedna.
Patients randomized to the lenalidomide/low dose dexamethasone arm received lenalidomide 25 mg/day, Days 1 to 21 every 28 days plus low dose dexamethasone – 40 mg/day on Days 1, 8, 15, and 22 every 28 days.
Bolesnici randomizirani u skupinu koja je primala lenalidomid/nisku dozu deksametazona primali su lenalidomid u dozi od 25 mg na dan od 1.do 21. dana svakih 28 dana i nisku dozu deksametazona – 40 mg na dan 1., 8., 15. i 22. dana svakih 28 dana.
Patients randomized to tocilizumab had fewer ACR30 flares and higher overall ACR responses than patients receiving placebo regardless of a history of prior biologic use.
Bolesnici randomizirani za liječenje tocilizumabom imali su manji broj pogoršanja upala na razini ACR30 te veće ukupne ACR odgovore nego bolesnici koji su primali placebo, neovisno o prethodnoj primjeni bioloških lijekova.
Patients receive one Ozurdex implant at a time, injected directly into the vitreous humour.
Bolesnici primaju jedan implantat Ozurdex, injektiran izravno u vitreoznu tekućinu.
Patients received 3 or 6 mg/kg infliximab as a
Bolesnici su kao uvodnu terapiju primili 3 doze infliksimaba u dozi od 3 mg/kg (u 0., 2. i 6. tjednu) ili 6 mg/kg (u 14.,
Patients received 3 or 6 mg/kg infliximab as a
Bolesnici su kao uvodnu terapiju primili 3- doze infliksimaba u dozi od 3 mg/kg (u 0., 2. i 6. tjednu) ili 6 mg/kg (u 14.,
Patients received a median of 5 cycles of maintenance treatment with pemetrexed and 3.5 cycles of placebo.
Bolesnici su primili medijan od 5 ciklusa terapije održavanja pemetrekseda i 3,5 ciklusa placeba.
Patients received a starting dose of Neparvis of 50 mg twice daily and were up-titrated to 100 mg twice daily, then to the target dose of 200 mg twice daily, with either a 3-week or a 6-week regimen.
Bolesnici su primali početnu dozu Neparvisa od 50 mg dvaput na dan te bili titrirani na 100 mg dvaput na dan, zatim na ciljnu dozu od 200 mg dvaput na dan, s režimom doziranja od 3 tjedna ili od 6 tjedana.
Patients received Arzerra as monthly intravenous infusions (Cycle 1 300 mg on day 1 and 1,000 mg on day 8, subsequent cycles: 1,000 mg on day 1 every 28 days) in combination with intravenous bendamustine 90 mg/m2 at days 1 and 2 every 28 days.
Bolesnici su primali lijek Arzerra u obliku mjesečnih intravenskih infuzija (1. ciklus: 300 mg 1. dana i 1000 mg 8. dana; sljedeći ciklusi: 1000 mg 1. dana svakih 28 dana) u kombinaciji s intravenskim bendamustinom u dozi od 90 mg/m2 1. i 2. dana svakih 28 dana.
Patients received Arzerra as monthly intravenous infusions (Cycle 1 300 mg on day 1 and 1,000 mg on day 8, subsequent cycles: 1,000 mg on day 1 every 28 days) in combination with intravenous bendamustine 90 mg/m2 on days 1 and 2 every 28 days.
Bolesnici su primali lijek Arzerra u obliku mjesečnih intravenskih infuzija (1. ciklus: 300 mg 1. dana i 1000 mg 8. dana; sljedeći ciklusi: 1000 mg 1. dana svakih 28 dana) u kombinaciji s intravenskim bendamustinom u dozi od 90 mg/m2 1. i 2. dana svakih 28 dana.
Patients received daily morning doses of G-CSF 10 μg/kg for 4 days prior to the first dose of plerixafor or placebo and on each morning prior to apheresis.
Bolesnici su svako jutro tijekom 4 dana prije prve doze pleriksafora ili placeba te svako jutro prije afereze primili dozu G-CSF-a od 10 μg/kg.
Patients received different doses of Revestive or standard treatment for 12 weeks.
Bolesnici su primili različite doze lijeka Revestive ili standardno liječenje tijekom 12 tjedana.
Patients received either 75 mg alirocumab Q2W or placebo in addition to their existing lipid-modifying therapy.
Bolesnici su uz postojeću terapiju koja modificira lipide primali ili alirokumab u dozi od 75 mg jednom svaka 2 tjedna ili placebo.
Patients received either alirocumab 75 mg Q2W or ezetimibe 10 mg once daily in addition to their existing statin therapy.
Bolesnici su uz postojeću terapiju koja modificira lipide primali ili alirokumab u dozi od 75 mg jednom svaka 2 tjedna ili ezetimib u dozi od 10 mg jednom dnevno.
Patients received either alirocumab 75 mg Q2W or placebo in addition to their existing lipid-modifying therapy.
Bolesnici su uz postojeću terapiju koja modificira lipide primali ili alirokumab u dozi od 75 mg jednom svaka 2 tjedna ili placebo.
Patients received either alirocumab at a dose of 150 mg Q2W or placebo in addition to their existing lipid-modifying therapy.
Bolesnici su uz postojeću terapiju koja modificira lipide primali ili alirokumab u dozi od 150 mg jednom svaka 2 tjedna ili placebo.
Patients received either Arzerra as monthly intravenous infusions (Cycle 1: 300 mg on day 1 and 1,000 mg on day 8.
Bolesnici su primali ili lijek Arzerra u obliku mjesečnih intravenskih infuzija (1. ciklus: 300 mg 1. dana i 1000 mg 8. dana; sljedeći ciklusi: 1000 mg
Patients received either lumacaftor/ivacaftor (n=62) or placebo (n=63) in addition to their prescribed CF therapies.
Bolesnici su primali lumakaftor/ivakaftor (n = 62) ili placebo (n = 63) osim svoje propisane terapije za cističnu fibrozu.
Patients received either Remsima or Remicade in addition to methotrexate for 30 weeks.
Ispitanici su primali bilo lijek Remsima, bilo Remicade kao dodatak uz metotreksat kroz 30 tjedana.
Patients received either travoprost 0.004% once daily or timolol 0.5% (or 0.25% for subjects younger than 3 years old) twice daily.
Bolesnici su primali travoprost 0,004% jedanput na dan ili timolol 0,5% (ili 0,25 % za ispitanike mlađe od 3 godine ) dvaput na dan.
Patients received either zoledronic acid 4 mg or placebo every four weeks for one year.
Bolesnici su primali 4 mg zoledronatne kiseline ili placebo svaka četiri tjedna tijekom jedne godine.
Patients received Humira 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate
Bolesnici su primali lijek Humira u dozi od 0,8 mg/kg svaki drugi tjedan (do najviše 40 mg),
Patients received low-dose acetylsalicylic acid prior to randomization and throughout the two CABG surgery studies.
Prije randomizacije i tijekom cijelog trajanja ta dva kirurška ispitivanja primjene kod operacije ugradnje arteriokoronarne premosnice bolesnici su primali nisku dozu acetilsalicilne kiseline.
Patients received placebo, 3 mg/kg or 10 mg/kg infliximab at weeks 0, 2 and 6, and then every 4 or 8 weeks thereafter.
Bolesnici su primili ili placebo ili infliksimab u dozi od 3 mg/kg odnosno 10 mg/kg 0., u 2. i 6. tjednu ispitivanja, a zatim svakih 4 ili 8 tjedana.
Patients received single subcutaneous weekly injections for 24 weeks.
Dobivali su jednu injekciju tjedno supkutano tijekom 24 tjedna.
Patients received SIRTURO (n = 79) or placebo (n = 81) for 24 weeks, both in combination with a preferred 5-drug background regimen (BR) consisting of ethionamide, kanamycin, pyrazinamide, ofloxacin, and cycloserine/terizidone.
Bolesnici su primili SIRTURO (n = 79) ili placebo (n = 81) tijekom 24 tjedna, oboje u kombinaciji s preferiranim osnovnim liječenjem s 5-lijekova (od engl.
Patients received the first dose of Xarelto at a minimum of 24 hours and up to 7 days (mean 4.7 days) after admission to the hospital, but as soon as possible after stabilisation of the ACS event, including revascularisation procedures and when parenteral anticoagulation therapy would normally be discontinued.
Bolesnici su primili prvu dozu lijeka Xarelto najmanje 24 sata i najviše 7 dana (srednja vrijednost 4,7 dana) nakon prijema u bolnicu, ali čim je to bilo moguće nakon stabilizacije akutnog koronarnog sindroma, uključujući postupke revaskularizacije i kada bi se obično prekinula antikoagulantna terapija.
Patients received the lower strength (70 mg/2,800 IU) of ADROVANCE (n=350) or FOSAMAX (alendronate) 70 mg (n=332) once a week; additional vitamin D supplements were prohibited.
Bolesnice su jedanput na tjedan primale ADROVANCE u nižoj dozi (70 mg/2800 IU) (n=350) ili FOSAMAX (alendronat) u dozi od 70 mg (n=332); dodatni nadomjestak vitamina D bio je zabranjen.
Patients received the lower strength (70 mg/2,800 IU) of FOSAVANCE (n=350) or FOSAMAX (alendronate) 70 mg (n=332) once a week; additional vitamin D supplements were prohibited.
Bolesnice su jedanput na tjedan primale FOSAVANCE u nižoj dozi (70 mg/2800 IU) (n=350) ili FOSAMAX (alendronat) u dozi od 70 mg (n=332); dodatni unos vitamina D bio je zabranjen.
Patients received the lower strength (70 mg/2800 IU) of VANTAVO (n=350) or FOSAMAX (alendronate) 70 mg (n=332) once a week; additional vitamin D supplements were prohibited.
Bolesnice su jedanput na tjedan primale VANTAVO u nižoj dozi (70 mg/2800 IU) (n=350) ili FOSAMAX (alendronat) u dozi od 70 mg (n=332); dodatni unos vitamina D bio je zabranjen.
Patients received this pre-selected regimen if not randomised to Vidaza.
Ako bolesnici nisu bili randomizirani na Vidazu, primili bi prethodno odabrani režim.
Patients received treatment for a minimum of 3 cycles and patients with stable disease or response after 3 cycles continued treatment for a further 3 cycles for a maximum of 6 cycles.
Bolesnici su primali liječenje tijekom najmanje 3 ciklusa, a bolesnici sa stabilnom bolešću ili odgovorom nakon 3 ciklusa nastavili su liječenje tijekom još 3 ciklusa do najviše 6 ciklusa.
Patients receiving acetylsalicylic acid & clopidogrel as per protocol*
Bolesnici koji su primali acetilsalicilatnu kiselinu i klopidogrel prema planu ispitivanja
Patients receiving any concomitant treatment containing bupropion or naltrexone
Bolesnici koji dobivaju istodobno liječenje s bupropionom ili naltreksonom
Patients receiving any kind of therapeutic anticoagulation and/or chronic therapy with non-steroidal anti-inflammatory drugs or anti-platelet agents were excluded from the REVEL NSCLC clinical trial.
U kliničko ispitivanje REVEL, provedeno u bolesnika s NSCLC-om, nisu bili uključeni ni bolesnici koji su primali bilo kakvu antikoagulantnu terapiju i/ili kroničnu terapiju nesteroidnim protuupalnim lijekovima ili antitromboticima.
Patients receiving Aptivus or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV-1 infection.
Bolesnici koji dobivaju Aptivus ili neku drugu antiretrovirusnu terapiju mogu nastaviti razvijati oportunističke infekcije i druge komplikacije HIV-1 infekcije.
Patients receiving Atriance should be monitored regularly for changes in blood cell counts and should receive adequate hydration if they are at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells).
Bolesnici koji primaju lijeka Atriance treba redoviti pratiti kako bi se uočile promjene u broju stanica u krvi te trebaju primiti redovitu hidrataciju, ako su izloženi riziku od sindroma lize tumora (komplikacija uslijed razgradnje stanica raka).
Patients receiving Atripla or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
U pacijenata koji primaju Atriplu ili neku drugu antiretrovirusnu terapiju mogu se i dalje razvijati oportunističke infekcije i druge komplikacije infekcije HIV-om, pa bi zbog toga trebali ostati pod strogim kliničkim nadzorom liječnika koji imaju iskustva u liječenju pacijenata s bolestima povezanim s HIV-om.
Patients receiving bosutinib should have liver function tests prior to treatment initiation and monthly for the first three months of treatment, and as clinically indicated.
Bolesnici koji primaju bosutinib moraju napraviti testove jetrene funkcije prije početka liječenja, zatim svaki mjesec tijekom prva tri mjeseca liječenja i kad god je to klinički indicirano.
Patients receiving BRINAVESS have a higher incidence of converting to atrial flutter within the first 2 hours post-dose.
Bolesnici koji primaju BRINAVESS imaju veću incidenciju konverzije u undulaciju atrija unutar prva 2 sata nakon davanja doze.
Patients receiving cardiac glucosides
Bolesnika koji uzimaju srčane glikozide
Patients receiving CellCept should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.
Bolesnike koji primaju CellCept potrebno je uputiti da odmah prijave bilo koji znak infekcije, neočekivanu pojavu modrica, krvarenje ili bilo koju drugu manifestaciju depresije koštane srži.
Patients receiving concomitant administration of monoamine oxidase inhibitors (MAOI).
Bolesnici koji primaju istodobno inhibitore monoaminooksidaze (MAOI).
Patients receiving concomitant non-liposomal irinotecan and CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital or carbamazepine have substantially reduced exposure to irinotecan (AUC reduction by 12% with St John’s wort, 57%-79% with phenytoin, phenobarbital, or carbamazepine) and SN-38 (AUC reduction by 42% with St John’s wort, 36%-92% with phenytoin phenobarbital, or carbamazepine).
Bolesnici koji istodobno primaju neliposomalni irinotekan i antikonvulzive koji induciraju enzim CYP3A4, fenitoin, fenobarbital ili karbamazepin, imaju znatno smanjenu izloženost irinotekanu (smanjenje AUC za 12% s gospinom travom, 57%-79% s fenitoinom, fenobarbitalom ili karbamazepinom) i metabolitu SN-38 (smanjenje AUC za 42% s gospinom travom, 36%-92% s fenitoinom, fenobarbitalom ili karbamazepinom).
Patients receiving concomitant parenteral aminoglycoside therapy (or any medication affecting renal excretion, such as diuretics) should be monitored as clinically appropriate taking into account the risk of cumulative toxicity.
Bolesnike koji primaju istodobnu terapiju parenteralnim aminoglikozidom (ili bilo kojim lijekom koji utječe na bubrežno izlučivanje, kao što su diuretici) treba pratiti na klinički primjeren način uzimajući u obzir rizik od kumulativne toksičnosti.
Patients receiving concomitant treatment with anticoagulants (e.g. warfarin, acenocoumarole) may be periodically monitored by complete blood counts (platelets), coagulation factors (PT/INR) and physical examination.
Bolesnike koji se istodobno liječe antikoagulansima (npr. varfarinom ili acenokumarolom) može se povremeno kontrolirati provjeravanjem kompletne krvne slike (trombocita), faktora koagulacije (PV/INR) i fizikalnim pregledom.
Patients receiving Cosentyx may receive concurrent inactivated or non-live vaccinations.
Bolesnici koji primaju Cosentyx mogu istodobno primati inaktivirana ili neživa cjepiva.
Patients receiving DepoCyte should be concurrently treated with corticosteroids (e.g. dexamethasone) to mitigate the symptoms of arachnoiditis (see section 4.8), which is a very common adverse reaction.
Bolesnike koji primaju DepoCyte treba istovremeno liječiti kortikosteroidima (npr. deksametazonom) radi ublažavanja simptoma arahnoiditisa (vidjeti dio 4.8), koji je česta nuspojava.
Patients receiving DMARDs, NSAIDS, or corticosteroids could continue them on stable doses.
Bolesnici koji su uzimali DMARD, NSAID ili kortikosteroide mogli su ih nastaviti uzimati u stabilnoj dozi.
Patients receiving Effentora concomitantly with moderate or strong CYP3A4 inhibitors should be carefully monitored for an extended period of time.
Bolesnike koji primaju Effentoru istovremeno s umjerenim ili jakim inhibitorima CYP3A4 potrebno je pažljivo nadzirati na dulje vrijeme.
Patients receiving eluxadoline also reported significant reductions in bowel movement frequency and abdominal bloating compared to placebo as demonstrated by changes from baseline in daily bowel movements and bloating score at Weeks 12 and
Bolesnici koji su primali eluksadolin također su prijavili značajna smanjenja u učestalosti pražnjenja crijeva i nadutosti abdomena u usporedbi s placebom što je dokazano promjenama u odnosu na početne vrijednosti u dnevnim pražnjenjima crijeva i ocjeni nadutosti u 12. i
Patients receiving Empliciti in combination with lenalidomide should adhere to the pregnancy prevention programme of lenalidomide.
Bolesnici koji primaju Empliciti u kombinaciji s lenalidomidom moraju se pridržavati programa za sprječavanje trudnoće kod primjene lenalidomida.
Patients receiving enzalutamide demonstrated a significantly higher total PSA response rate (defined as a ≥ 50% reduction from baseline), compared with patients receiving placebo, 78.0% versus 3.5% (difference = 74.5%, p < 0.0001).
Bolesnici koji su primali enzalutamid pokazali su značajno višu ukupnu stopu odgovora PSA (definirano kao ≥ 50%-tno smanjenje u odnosu na početne vrijednosti), u usporedbi s bolesnicima koji su primali placebo, 78,0% naspram 3,5% (razlika = 74,5%, p < 0,0001).
Patients receiving Esbriet should have their liver function checked before and regularly during treatment.
Prije i redovito tijekom liječenja treba kontrolirati funkciju jetre u bolesnika koji primaju lijek Esbriet.
Patients receiving factor VIII products may sometimes develop antibodies to factor VIII (also known as factor VIII inhibitors), which may prevent the factor VIII product from working properly.
Bolesnici koji primaju lijekove s faktorom VIII mogu ponekad razviti protutijela na faktor VIII (također poznati kao inhibitori faktora VIII), koja mogu spriječiti ispravno djelovanje lijeka s faktorom VIII.